Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Severe Eosinophilic Esophagitis
NCT00523354Phase 2Completed
- Sponsor
- Swiss Eosinophilic Esophagitis Study Group
- Start
- Aug 2007
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in eosinophilic esophagitis (EoE), sponsored by Swiss Eosinophilic Esophagitis Study Group. Primary endpoint: Tissue eosinophilia before and after therapy. Started Aug 2007; status: completed.
02
Drugs
infliximab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT00523354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523354.